Targeting of KRAS by miR-30b-5p or miR-30e-5p inhibits cell growth, proliferation and migration in the context of HNSCC, which suggests the potential of miRNA-based therapeutics or the combination of simultaneous targeting of multiple mRNAs with tumor-targeted therapies or resistance mitigation strategies. Here, KRAS is linked to neoplasm.